Value in health regional issues · 2026
Cost-Utility Analysis of the Treatment With Ataluren Plus Standard of Care Compared With Standard of Care Alone in Patients With Duchenne Muscular Dystrophy in Brazil.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roesch Eliane W, Colpani Verônica, Dória Grace Anne A, de Oliveira Klébya Hellen D, Oliveira Catia, Peixoto Henry M, Oliveira Ana Flávia de M
Аннотация
OBJECTIVES: to evaluate the cost-utility of ataluren plus standard of care (SoC) for treating patients with nonsense mutation Duchenne muscular dystrophy from the Brazilian public health system perspective.
METHODS: A semi-Markov model, comprising 5 states, was developed to estimate the incremental cost per quality-adjusted life-years (QALYs) of ataluren plus SoC compared with SoC alone. A 48-year time horizon was used in the base-case analysis, considering annual cycles. Costs were expressed as international dollars (Int$) applying the purchasing power parity conversion rate (Brazilian purchasing power parity of 2.44 BRL/Int$ in 2023). The transition probabilities and utility data were obtained from previous studies, and costs were based on data from a microcosting study and the Brazilian Drug Market Regulation Chamber. Both costs and QALYs were discounted using a rate of 5%. Parameter uncertainty was assessed through deterministic and probabilistic sensitivity analyses.
RESULTS: Ataluren plus SoC leads to incremental 0.503 QALYs and incremental costs of Int$13 298 877.45, resulting in an incremental cost-utility ratio of Int$26 415 910.08/QALY. According to the deterministic sensitivity analysis, utilities related to the state's health progression of the model were the parameter that most significantly influenced the incremental cost-utility ratio. In the probabilistic sensitivity analysis, all estimates were above the current willingness-to-pay threshold of Int$49 180.33 per QALY for rare diseases.
CONCLUSIONS: Ataluren plus SoC for treating nonsense mutation Duchenne muscular dystrophy patients was not a cost-effective intervention compared with SoC alone from the perspective of the Brazilian public health system.
METHODS: A semi-Markov model, comprising 5 states, was developed to estimate the incremental cost per quality-adjusted life-years (QALYs) of ataluren plus SoC compared with SoC alone. A 48-year time horizon was used in the base-case analysis, considering annual cycles. Costs were expressed as international dollars (Int$) applying the purchasing power parity conversion rate (Brazilian purchasing power parity of 2.44 BRL/Int$ in 2023). The transition probabilities and utility data were obtained from previous studies, and costs were based on data from a microcosting study and the Brazilian Drug Market Regulation Chamber. Both costs and QALYs were discounted using a rate of 5%. Parameter uncertainty was assessed through deterministic and probabilistic sensitivity analyses.
RESULTS: Ataluren plus SoC leads to incremental 0.503 QALYs and incremental costs of Int$13 298 877.45, resulting in an incremental cost-utility ratio of Int$26 415 910.08/QALY. According to the deterministic sensitivity analysis, utilities related to the state's health progression of the model were the parameter that most significantly influenced the incremental cost-utility ratio. In the probabilistic sensitivity analysis, all estimates were above the current willingness-to-pay threshold of Int$49 180.33 per QALY for rare diseases.
CONCLUSIONS: Ataluren plus SoC for treating nonsense mutation Duchenne muscular dystrophy patients was not a cost-effective intervention compared with SoC alone from the perspective of the Brazilian public health system.